Nektar(US:NKTR) ZACKS·2025-05-08 23:25Core Viewpoint - Nektar Therapeutics reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.18, indicating a negative earnings surprise of -22.22% [1] Financial Performance - The company posted revenues of $10.46 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 40.47%, and a significant decline from $21.64 million in the same quarter last year [2] - Over the last four quarters, Nektar has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - Nektar shares have declined approximately 34.9% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current Zacks Rank for Nektar is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $17.76 million, and for the current fiscal year, it is -$0.70 on revenues of $70.05 million [7] - The trend of estimate revisions for Nektar is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Nektar belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]